Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can simple scans replace expensive scans for obesity?

NCT ID NCT07776678

Knowledge-focused Sponsor: Foundation for the National Institutes of Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study evaluates how well different devices—like bioelectrical impedance scales, 3D body scanners, and manual tape measurements—measure body fat and muscle compared to gold-standard methods like DXA and MRI. It will enroll 300 healthy adults with a BMI between 18.5 and 45. The goal is to see if simpler, cheaper tools can reliably assess body composition, which could make obesity diagnosis more accessible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to more accurate, accessible, and affordable ways to diagnose obesity and monitor body composition, potentially improving personalized health assessments.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly change patient care. The accuracy of devices may vary, and results might not apply to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A diverse sample of adults will be recruited for participation in the US. Stratification will occur based on sex and BMI, with additional targets to promote recruitment of a variety of ages and adequate representation of racial and ethnic categories. For race and ethnicity, the goal will be to obtain a distribution approximately equal to the demographics of the United States, with selective oversampling employed as needed. For BMI, the following percentages will be used as approximate goals for the sample (18.50-19.99, None; 20.00-24.99, 20%; 25.00-29.99, 35%; 30.00-34.99, 25%; 35.00-39.99, 13.30%; 40.00-44.99, 6.70%; ≥45, None). However, the distribution of BMI and other demographic characteristics will be monitored as the study progresses in case adjustment is needed.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Being willing to provide written informed consent prior to participation Being willing to complete the study visits and comply with the study procedures * Being willing to travel to the various study locations for On-site, DXA, MRI, and Phlebotomy visits * Being willing to change into appropriate form-fitting clothing for 3DO assessments and/or appropriate gowns for DXA and MRI imaging * Must have a BMI within the range of 18.5 - 45 kg/m2 * Being willing to refrain from all food, drink, and substances for 8 hours prior to the On-site visit(s) and phlebotomy visit * Being willing to refrain from all food, drink, and substances for 4 hours prior to the DXA and MRI scan visits * Being willing to refrain from any exercise or vigorous physical activity for 24 hours prior to all visits * Stable weight (no more than 5 kg change) for 3 months prior to screening * If recruited in the Phoenix, AZ area, participants must be willing to drive yourself to the Phoenix Office location for the On-site Visits 1 and 2 (if applicable) located at the Exponent Phoenix Office. Exclusion Criteria: * Being pregnant or attempting to become pregnant * Having medical implants, such as a pacemaker or metal joint replacements, or other metal implants contraindicated for MRI * Cosmetic implants, such as breast implants * Having a height greater than DXA scanning limit (77 inches) * Having a body weight greater than indicated for the equipment (400 lbs) * Prior amputation or major body-altering surgery that could invalidate body composition estimates * Having claustrophobia or a history of claustrophobia * Known HIV infection * Known Lipodystrophy * Known hydration abnormality (e.g., significant edema, end-stage renal disease, end-stage liver disease) * Severe illness or life-threatening conditions such as end-stage kidney, liver, lung disease, NYHA III-IV heart failure, or active malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    3 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Exponent Boston

    RECRUITING

    Boston, Massachusetts, 01760, United States

    Contact Email: •••••@•••••

  • Exponent Menlo Park

    NOT_YET_RECRUITING

    Menlo Park, California, 94025, United States

  • Exponent Phoenix

    RECRUITING

    Phoenix, Arizona, 85027, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.